Despite this low frequency of BRAF mutations in lung brain metastasis, regression of both visceral and brain metastases by BRAF inhibitor vemurafenib was reported in a patient with a BRAF V600E-mutated NSCLC (85). Here, BRAF is linked to non-small cell lung carcinoma.